NEOS Neos Therapeutics Inc.

8.40
-0.30  -3%
Previous Close 8.70
Open 8.60
Price To book 9.33
Market Cap 235877334
Shares 28,080,635
Volume 1,747,430
Short Ratio 8.37
Av. Daily Volume 650,962

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)

Latest News

  1. Corporate News Blog - Neos Therapeutics Receives FDA’s Approval for Adzenys ER(TM) Extended-Release Oral Suspension, its Third Treatment for ADHD
  2. Neos Therapeutics ADHD Drug Adzenys Receives Approval in US
  3. Neos Therapeutics shares fall after FDA approves new formulation of ADHD drug
  4. Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
  5. 5 of the Best Stocks Under $10 for 2017
  6. Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
  7. Neos Therapeutics to Participate in Three September Conferences
  8. 'Date' These Potential Biotech Winners
  9. What Falling Estimates & Price Mean for Cardiome (CRME)
  10. Neos Therapeutics reports 2Q loss
  11. Neos Therapeutics Reports Second Quarter 2017 Financial Results
  12. Investor Network: Neos Therapeutics, Inc. to Host Earnings Call
  13. Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017
  14. Neos Therapeutics Announces Pricing of Underwritten Public Offering of $32.4 Million of Common Stock
  15. Neos Therapeutics Announces Proposed Offering of Common Stock
  16. Shire wins U.S. approval for long-acting ADHD drug
  17. Two Red Hot Biotechs With Big Near-term Catalysts Ahead

SEC Filings

  1. 8-K - Current report 171088679
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171063081
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016460
  4. 8-K - Current report 171013219
  5. EFFECT - Notice of Effectiveness 17960896
  6. 424B3 - Prospectus [Rule 424(b)(3)] 17960339
  7. S-3 - Registration statement under Securities Act of 1933 17942719
  8. 8-K - Current report 17936603
  9. 424B5 - Prospectus [Rule 424(b)(5)] 17936268
  10. CT ORDER - Confidential treatment order 17934208